Drug Approval
Concept
Vocabulary Service
Overview
subject area of
-
A review of the two major regulatory pathways for non-proprietary low-molecular-weight heparins Journal Articles
-
Advancing Novel Molecular Imaging Agents from Preclinical Studies to First-in-Humans Phase I Clinical Trials in Academia—A Roadmap for Overcoming Perceived Barriers Journal Articles
-
Alternatives to Placebo-Controlled Trials Journal Articles
-
Biosimilars for psoriasis: clinical studies to determine similarity Journal Articles
-
Biosimilars for psoriasis: preclinical analytical assessment to determine similarity Journal Articles
-
Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice Journal Articles
-
Canada’s laws on pharmaceutical intellectual property: the case for fundamental reform: Figure 1: Journal Articles
-
Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016 Journal Articles
-
Clinical and Technical Considerations for Brain PET Imaging for Dementia Journal Articles
-
Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges Journal Articles
-
Determining optimal sample sizes for multistage adaptive randomized clinical trials from an industry perspective using value of information methods Journal Articles
-
Do we need a new approach to making vaccine recommendations? Journal Articles
-
Does GLP enhance the quality of toxicological evidence for regulatory decisions?: TABLE 1. Journal Articles
-
Ebola Virus in West Africa: Waiting for the Owl of Minerva Journal Articles
-
Emergency use authorisation for COVID-19 vaccines: lessons from Ebola Journal Articles
-
Engaging specialist oncologists in the assessment of oncology drugs in Canada Journal Articles
-
Establishing Therapeutic Equivalence of Complex Pharmaceuticals: The Case of Dabigatran Journal Articles
-
Evaluating Cost-Effectiveness: An Essential Part of New Cancer Drug Approvals Journal Articles
-
Exclusive Drug Labeling Rights as a New Incentive for Contribution to a Communal Biomarker Resource Journal Articles
-
Expert consensus recommendations on the use of randomized clinical trials for drug approval in psychiatry- comparing trial designs Journal Articles
-
Genetic and Chemical Screening in Human Blood Serum Reveals Unique Antibacterial Targets and Compounds against Klebsiella pneumoniae Journal Articles
-
Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies Conferences
-
Harmonization of HTA--based reimbursement and regulatory approval activities: a qualitative study. Journal Articles
-
Harmonization of reimbursement and regulatory approval processes: a systematic review of international experiences Journal Articles
-
INDs for PET Molecular Imaging Probes—Approach by an Academic Institution Journal Articles
-
In Vitro Testing for Orally Inhaled Products: Developments in Science-Based Regulatory Approaches Journal Articles
-
Is the GAIN Act a turning point in new antibiotic discovery? Journal Articles
-
Model‐Informed Drug Development for Anti‐Infectives: State of the Art and Future Journal Articles
-
New Antithrombotic Drugs Journal Articles
-
New approaches to rewarding pharmaceutical innovation Journal Articles
-
New treatments for dementia. Myth, magic, and science. Journal Articles
-
Objective Responses in Patients with Malignant Melanoma or Renal Cell Cancer in Early Clinical Studies Do Not Predict Regulatory Approval Journal Articles
-
Optimal sample size determinations from an industry perspective based on the expected value of information Journal Articles
-
Oral anticoagulant use in addition to antiplatelet therapy for secondary prevention in acute coronary syndrome: current perspectives Journal Articles
-
Pediatric drug data in Canadian drug monographs: a descriptive analysis Journal Articles
-
Phase 4 research: what happens when the rubber meets the road? Journal Articles
-
Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of 111In-BzDTPA-pertuzumab Journal Articles
-
Real-world studies no substitute for RCTs in establishing efficacy Journal Articles
-
Regional Approaches to Expedited Drug Development and Review: Can Regulatory Harmonization Improve Outcomes? Journal Articles
-
Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology Journal Articles
-
Sensible guidelines for the conduct of large randomized trials Journal Articles
-
Single pivotal trials with few corroborating characteristics were used for FDA approval of cancer therapies Journal Articles
-
Surrogate Markers in Clinical Studies: Problems Solved or Created? Journal Articles
-
Switching to extended half‐life products in Canada – preliminary data Journal Articles
-
Targeting of human cancer stem cells predicts efficacy and toxicity of FDA-approved oncology drugs Journal Articles
-
The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020 Journal Articles
-
The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 Years — United States, May 2021 Journal Articles
-
The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years — United States, November 2021 Journal Articles
-
The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine — United States, December 2020 Journal Articles
-
The Advisory Committee on Immunization Practices’ Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines — United States, 2021 Journal Articles
-
The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs Journal Articles
-
The Data and Safety Monitoring Committee: Some final thoughts Journal Articles
-
The Guideline-Policy Gap in Direct-Acting Oral Anticoagulants Usage in Atrial Fibrillation: Evidence, Practice, and Public Policy Considerations Journal Articles
-
The Opportunity Cost of Capital Journal Articles
-
The Price We Pay for Progress: A Meta-Analysis of Harms of Newly Approved Anticancer Drugs Journal Articles
-
The United States Food and Drugs Administration Approves a Generic Enoxaparin Journal Articles
-
The Vioxx® legacy: Enduring lessons from the not so distant past Journal Articles
-
The cost of drug development: A systematic review Journal Articles
-
The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials Journal Articles
-
Time for a regulatory framework for pediatric medications in Canada Journal Articles
-
Transforming an Academic Radiochemistry Facility for Positron Emission Tomography Drug cGMP Compliance Journal Articles
-
Trends in paediatric clinical pharmacology data in US pharmaceutical labelling Journal Articles
-
Trends in pregnancy labeling and data quality for US-approved pharmaceuticals Journal Articles
-
Unwarranted claims of drug efficacy in pharmaceutical sales visits: are drugs approved on the basis of surrogate outcomes promoted appropriately? Journal Articles
-
Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2021 Journal Articles